雷贝拉唑联合莫沙必利治疗反流性食管炎临床观察

目的探讨雷贝拉唑联合莫沙必利治疗反流性食管炎的近期疗效和安全性。方法将经确诊的反流性食管炎患者110例随机分成治疗组55例和对照组55例，治疗组雷贝拉唑10mg，早晚各1次，餐前服用；莫沙必利5mg，3次／a，餐前半小时服用。对照组奥美拉唑20mg，1次／a，餐前服用；莫沙必利服用方法同上。两组治疗6周，观察临床疗效和安全性。结果治疗组总有效率（94．5％）显著高于对照组，（76．4％），（P〈0．05）。结论雷贝拉唑联合莫沙必利治疗反流性食管炎临床症状改善迅速，临床疗效优于奥美拉唑联合莫沙必利。

Clinical observation on rabeprazole combined with mosapride in treatment of reflux esophagitis

Objective To study the the efficacy and safety of joint rabeprazole mosapride treatment of reflux esophagitis(RE). Methods 110 patients Confirmed by endoscopy reflux esophagitis were randomly divided into treatment group and control group 55 cases. Treatment group:oral rabeprazole 10mg, sooner or later, a second fasting taking each mosapride 5mg,3 times/day, fasting and a half hours to take; control group: omeprazole 20mg/day, taken before meals ,mosapride taking followed. 2 groups of patients were completed 6 weeks of treatment ,the clinical efficacy and safety were observed. Results The clinical total effective rate of symptom relief( symptom improvement and endoscopic remission and mucosal lesions ) were 94.5％ for the treatment group ( 52/55 ), control group 76.4％ ( 42/55), the efficiency of the treatment group was superior in the control group ( P ＜ 0.05 ). Conclusion Rabeprazole joint mosapride treatment of reflux esophagitis could improve symptoms rapidly,and clinical efficacy was superior to omeprazole mosapride treatment of reflux esophagitis, and was safe and reliable.